search
Back to results

[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET

Primary Purpose

Depression

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
18F-PF-06445974
Sponsored by
National Institute of Mental Health (NIMH)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Depression focused on measuring PET Imaging, Depression, Phosphodiesterase-4

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

INCLUSION CRITERIA: Patients: In order to be eligible for this study, MDD participants must meet all of the following criteria: 18 to 70 years of age. Female participants of childbearing potential must be using a medically acceptable means of contraception. Be in good general health as evidenced by medical history and physical examination. Stable medical conditions as assessed by their primary care provider (PCP) and/or in-house clinician are permitted to join the study. Each participant must have a level of understanding sufficient to agree to all required tests and examinations and sign an informed consent document. All participants must have undergone a screening assessment under protocol 01-M-0254, The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Participants . Participants must fulfill DSM-5 criteria for major depression (MDD) without psychotic features, as based on clinical assessment and structured diagnostic interview (SCID-P). Participants must have an initial score on the MADRS >= 18 or HAM-D >= 15 within one week of study entry. Participants must be experiencing an MDE lasting at least four weeks. All MDD participants must have a PCP or psychiatrist in the community. Participants must have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists. Participants must agree to adhere to the lifestyle considerations. Healthy Controls: In order to be eligible to participate in this study, control subjects must meet all of the following criteria: Aged 18 to 70 years old. Female participants of childbearing potential must be using a medically acceptable means of contraception. Able to provide informed consent. Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment. Be enrolled in 01M0254, The Evaluation of Participants with Mood and Anxiety Disorders and Healthy Volunteers or 17M0181, Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies . Have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists. Agree to adhere to the lifestyle considerations. EXCLUSION CRITERIA: Participants with MDD who meet any of the following criteria will be excluded from participation in this study: Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). Any lab value that is two-times the upper limit or even lower values in the investigator s judgment. Creatinine level >1.3 mg/dL. Participants must be free of all prohibited medications for at least two weeks (5 weeks for aripiprazole, brexpiprazole, fluoxetine) prior to screen visit. These medications include antidepressants, antipsychotics, anxiolytics, psychotropic drugs not otherwise specified (including herbal products), and sedatives/hypnotics. Current psychotic features, a diagnosis of schizophrenia or any other psychotic disorder as defined in the DSM-5. Participants with a history of psychiatric inpatient hospitalization within the past year. Participants with a history of DSM-5 substance use disorder (except for caffeine or nicotine dependence) within the preceding three months. In addition, participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs function of daily life. Participants who, in the investigator s judgment, pose a current serious suicidal or homicidal risk. Participants with suicidal ideation within the past 6 months. Participants with suicidal behavior within the past 12 months. Participants who have a history of aggressive behavior towards others. Participants who have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy). HIV infection. Pregnancy. Are unable to travel to the NIH. Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits. Have an inability to lie flat and/or lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the participant during the screening visit. Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye. Be NIMH staff or an NIH employee who is a subordinate/relative/co-worker of the investigators. Healthy controls who meet any of the following criteria will be excluded from participation in this study: Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). Participants must be free of all prohibited medications or at least two weeks (5 weeks for aripiprazole, brexpiprazole, fluoxetine) prior to screen visit. These medications include antidepressants, antipsychotics, anxiolytics, psychotropic drugs not otherwise specified (including herbal products), and sedatives/hypnotics. Participants with a history of DSM-5 substance use disorder (except for caffeine or nicotine dependence) within the preceding three months. In addition, participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs function of daily life. Participants who have a history of major depressive disorder. Participants who have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy). HIV infection. Pregnancy. Are unable to travel to the NIH. Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits. Have an inability to lie flat and/or lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the participant during the screening visit. Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye. Be NIMH staff or an NIH employee who is a subordinate/relative/co-worker of the investigator.

Sites / Locations

  • National Institutes of Health Clinical CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

one arm

Arm Description

All subjects will receive the same tests

Outcomes

Primary Outcome Measures

To measure distribution volume
Target quantification

Secondary Outcome Measures

To determine the optimal length
Target quantification
To measure whole-brain distribution volume in retest
Target quantification
measure clinical rating scales and PDE4B binding
Assess the severity of depression

Full Information

First Posted
January 27, 2023
Last Updated
August 10, 2023
Sponsor
National Institute of Mental Health (NIMH)
search

1. Study Identification

Unique Protocol Identification Number
NCT05703685
Brief Title
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
Official Title
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
Study Type
Interventional

2. Study Status

Record Verification Date
August 8, 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 22, 2023 (Actual)
Primary Completion Date
October 3, 2024 (Anticipated)
Study Completion Date
April 11, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Institute of Mental Health (NIMH)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Background: Major depressive disorder (MDD) is a psychiatric condition. People with MDD have occasional bouts of depressive symptoms; these bouts are called major depressive episodes (MDEs). Researchers want to know if people having MDEs have lower levels of an enzyme called PDE4B in their brains. Objective: To find out (1) if PDE4B can be detected in a person s brain using a special scanning method and (2) if brain PDE4B levels are lower in people having an MDE. Eligibility: People aged 18-70 years with MDD. Healthy volunteers are also needed. Design: Participants will have up to 5 clinic visits. Participants will be screened. They will have a physical exam with blood tests. They will have a test of their heart function. Some participants may have a psychiatric assessment; they will answer questions about their state of mind and related topics. Participants will have magnetic resonance imaging (MRI) of the brain. They will lie on a table that slides into a metal cylinder. Participants will have a positron emission tomography (PET) scan. A needle will be used to guide a thin plastic tube (catheter) into a vein in one arm. An experimental substance called a radioactive tracer ([18F]PF-06445974) will be injected through the catheter. Participants will lie on a table that slides into a doughnut-shaped machine. The scan will last up to 4 hours with a 15-minute break. Participants blood pressure, heart rate, and breathing will be monitored before, during, and after the PET scan. A second catheter will be inserted in the artery of the wrist so blood can be drawn during the scan. Some participants may return for a second PET scan. https://nimhcontent.nimh.nih.gov/start/surveys/?s=KE88DXXPLDFHHTF8
Detailed Description
Study Description: This study will examine whether phosphodiesterase 4B (PDE4B) can be accurately quantified in the human brain and whether it is reduced in the brain of individuals with major depressive disorder (MDD). Objectives: Primary Objective: To determine whether PDE4B is reduced in the brains of individuals with MDD experiencing a major depressive episode (MDE). Secondary Objectives: To determine the optimal length of scanning and the retest variability and reliability of [18F]PF-06445974, and whether PDE4B binding correlates with clinical rating scales. Endpoints: Primary Endpoint: measurement of PDE4B density (distribution volume VT) in the brains of individuals with MDD compared to healthy volunteers Secondary endpoints: To determine the optimal length for PDE4B scans with [18F]PF-06445974 PET scans in healthy volunteers To measure whole-brain VT of PDE4B in a retest setting. To assess the relationship between clinical rating scales and PDE4B binding

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression
Keywords
PET Imaging, Depression, Phosphodiesterase-4

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
56 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
one arm
Arm Type
Other
Arm Description
All subjects will receive the same tests
Intervention Type
Drug
Intervention Name(s)
18F-PF-06445974
Intervention Description
Injected IV followed by PET scanning
Primary Outcome Measure Information:
Title
To measure distribution volume
Description
Target quantification
Time Frame
36 months
Secondary Outcome Measure Information:
Title
To determine the optimal length
Description
Target quantification
Time Frame
36 months
Title
To measure whole-brain distribution volume in retest
Description
Target quantification
Time Frame
36 months
Title
measure clinical rating scales and PDE4B binding
Description
Assess the severity of depression
Time Frame
36 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
INCLUSION CRITERIA: Patients: In order to be eligible for this study, MDD participants must meet all of the following criteria: 18 to 70 years of age. Female participants of childbearing potential must be using a medically acceptable means of contraception. Be in good general health as evidenced by medical history and physical examination. Stable medical conditions as assessed by their primary care provider (PCP) and/or in-house clinician are permitted to join the study. Each participant must have a level of understanding sufficient to agree to all required tests and examinations and sign an informed consent document. All participants must have undergone a screening assessment under protocol 01-M-0254, The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Participants . Participants must fulfill DSM-5 criteria for major depression (MDD) without psychotic features, as based on clinical assessment and structured diagnostic interview (SCID-P). Participants must have an initial score on the MADRS >= 18 or HAM-D >= 15 within one week of study entry. Participants must be experiencing an MDE lasting at least four weeks. All MDD participants must have a PCP or psychiatrist in the community. Participants must have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists. Participants must agree to adhere to the lifestyle considerations. Healthy Controls: In order to be eligible to participate in this study, control subjects must meet all of the following criteria: Aged 18 to 70 years old. Female participants of childbearing potential must be using a medically acceptable means of contraception. Able to provide informed consent. Be in good general health, as evidenced by medical history and physical examination, and have no cognitive impairment. Be enrolled in 01M0254, The Evaluation of Participants with Mood and Anxiety Disorders and Healthy Volunteers or 17M0181, Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies . Have their radial artery pulse checked for the presence of adequate ulnar collateral flow and the absence of any metal or foreign objects in both wrists. Agree to adhere to the lifestyle considerations. EXCLUSION CRITERIA: Participants with MDD who meet any of the following criteria will be excluded from participation in this study: Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). Any lab value that is two-times the upper limit or even lower values in the investigator s judgment. Creatinine level >1.3 mg/dL. Participants must be free of all prohibited medications for at least two weeks (5 weeks for aripiprazole, brexpiprazole, fluoxetine) prior to screen visit. These medications include antidepressants, antipsychotics, anxiolytics, psychotropic drugs not otherwise specified (including herbal products), and sedatives/hypnotics. Current psychotic features, a diagnosis of schizophrenia or any other psychotic disorder as defined in the DSM-5. Participants with a history of psychiatric inpatient hospitalization within the past year. Participants with a history of DSM-5 substance use disorder (except for caffeine or nicotine dependence) within the preceding three months. In addition, participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs function of daily life. Participants who, in the investigator s judgment, pose a current serious suicidal or homicidal risk. Participants with suicidal ideation within the past 6 months. Participants with suicidal behavior within the past 12 months. Participants who have a history of aggressive behavior towards others. Participants who have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy). HIV infection. Pregnancy. Are unable to travel to the NIH. Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits. Have an inability to lie flat and/or lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the participant during the screening visit. Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye. Be NIMH staff or an NIH employee who is a subordinate/relative/co-worker of the investigators. Healthy controls who meet any of the following criteria will be excluded from participation in this study: Clinically significant abnormalities on EKG or laboratory testing. This includes CBC and acute care panel (Na, K, Cl, CO2, creatinine, glucose, urea nitrogen). Participants must be free of all prohibited medications or at least two weeks (5 weeks for aripiprazole, brexpiprazole, fluoxetine) prior to screen visit. These medications include antidepressants, antipsychotics, anxiolytics, psychotropic drugs not otherwise specified (including herbal products), and sedatives/hypnotics. Participants with a history of DSM-5 substance use disorder (except for caffeine or nicotine dependence) within the preceding three months. In addition, participants must not have substance use disorder or alcohol use disorder. However, alcohol or cannabis use by themselves are not exclusion criteria, unless that use impairs function of daily life. Participants who have a history of major depressive disorder. Participants who have an unstable medical condition that, in the opinion of the investigators, makes participation unsafe (e.g., an active infection or untreated malignancy). HIV infection. Pregnancy. Are unable to travel to the NIH. Have recent exposure to radiation related to research (e.g., PET from other research) that, when combined with this study, would be above the allowable limits. Have an inability to lie flat and/or lie still on the camera bed for at least two hours, including claustrophobia, overweight greater than the maximum for the scanner, and uncontrollable behavioral symptoms, which will be screened by an interview with the participant during the screening visit. Are unable to have an MRI scan (e.g., because of pacemakers or other implanted electrical devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), permanent eyeliner, implanted delivery pumps, shrapnel fragments, or metal fragments in the eye. Be NIMH staff or an NIH employee who is a subordinate/relative/co-worker of the investigator.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Maria D Ferraris Araneta, C.R.N.P.
Phone
(301) 496-9423
Email
ferrarism@mail.nih.gov
First Name & Middle Initial & Last Name or Official Title & Degree
Robert B Innis, M.D.
Phone
(301) 594-1368
Email
robert.innis@nih.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert B Innis, M.D.
Organizational Affiliation
National Institute of Mental Health (NIMH)
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Institutes of Health Clinical Center
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20892
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
Phone
800-411-1222
Ext
TTY dial 711
Email
ccopr@nih.gov

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
.The results will be submitted to ClinicalTrials.gov
IPD Sharing Time Frame
18 months after closure of protocol
IPD Sharing Access Criteria
BTRIS
Links:
URL
https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_000676-M.html
Description
NIH Clinical Center Detailed Web Page

Learn more about this trial

[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET

We'll reach out to this number within 24 hrs